Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 221-678-6 | CAS number: 3184-13-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Based on the results of the study, a no-observed-adverse effect level (NOAEL) of 3445 and 3986 mg/kg body weight/day was established for male and female rats.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1993-09-22 to 1994-06-22 and 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- other: Japanese guidelines for Toxicity Studies Required for Applications for Approval to Manufacture (Import) Drugs (MHW, 1989), and with the Revision of Guidelines for Single-Dose and Repeated-Dose Toxicity Studies (MHW, 1993).
- GLP compliance:
- yes
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: Kyowa Hakko Bio Co., Ltd. Batches 080926 and 083019
- Expiration date of the lot/batch: practically stable
- Purity test date: 1993-08-27
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: stable
- Stability under test conditions: stable
- Solubility and stability of the test substance in the solvent/vehicle: highly soluble
-
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: none
Purity >/= 99.9 % - Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Seventy-five male and 75 female Crj:CD (SD) strain specific pathogen free rats (4 weeks of age) were purchased from Charles River Japan, Inc. and allowed to acclimate for 2 weeks. Animals were maintained at 22 °C, with a relative humidity of 55%, and food and water were provided ad libitum. At 6 weeks of age, 60 healthy males and 60 healthy females were selected for the study.
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- Rats (12/sex/group) were administered L-ornithine monohydrochloride in the diet at concentrations of 0 (basal diet control), 1.25%, 2.5%, or 5.0% for 13 weeks. An additional 6 animals/sex/group were administered the basal diet or 5.0% L-ornithine monohydrochloride for 13 weeks, followed by the basal diet control for an additional 5 weeks (recovery period). The highest dose was selected based on an estimated 200-fold factor from the maximum anticipated exposure in humans.
- Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 134 weeks; 90 d as to repeated dose oral toxicity
- Frequency of treatment:
- Treatment: by food ad libitum
- Dose / conc.:
- 12 500 mg/kg diet
- Remarks:
- Equivalent to 1.25 % in the diet
- Dose / conc.:
- 25 000 mg/kg diet
- Remarks:
- Equivalent to 2.5 % in the diet
- Dose / conc.:
- 50 000 mg/kg diet
- Remarks:
- Equivalent to 5 % in the diet
- No. of animals per sex per dose:
- 12
An additional 6 animals/sex/group were administered the basal diet or 5.0% L-ornithine monohydrochloride for 13 weeks, followed by the basal diet control for an additional 5 weeks (recovery period). - Control animals:
- yes, plain diet
- Details on study design:
- - Dose selection rationale: Low toxicity expected.
- Rationale for selecting satellite groups: random
- Post-exposure recovery period in satellite groups: 5 weeks - Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: weekly (indicated in the related study report B-2523-1)
- Cage side observations checked in table were included. (in the related study report B-2523-1)
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: twice daily during treatment period, once daily during recovery period
BODY WEIGHT: Yes
- Time schedule for examinations: weekly, both treatment period and recovery period
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: prior to administration, week 13 of treatment period, week 5 of recovery period
- Dose groups that were examined: all
HAEMATOLOGY: Yes
- Time schedule for collection of blood: last day of treatment period
- Anaesthetic used for blood collection: Not specified
- Animals fasted: Yes
- How many animals: all
- Parameters checked in table were examined. (in the related study report B-2523-1)
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: last day of treatment period, end of recovery period
- Animals fasted: Yes
- Parameters checked in table were examined. (in the related study report B-2523-1)
URINALYSIS: Yes
- Time schedule for collection of urine: and 13 of the treatment
period, and on week 5 of the recovery period.
- Metabolism cages used for collection of urine: Not specified
- Animals fasted: Yes
- Parameters checked in table were examined. (in the related study report B-2523-1)
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: twice daily during the treatment period, and once daily during the recovery period
- Dose groups that were examined: all
- Battery of functions tested: sensory activity / grip strength / motor activity / other: abnormal behaviour
IMMUNOLOGY: No
OTHER: - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (Table see the related study report B-2523-1)
HISTOPATHOLOGY: Yes Yes (Table see the related study report B-2523-1) - Statistics:
- Quantitative data were analyzed for homogeneity of variance by the Bartlett method. Data with homogeneous variance were subjected to an analysis of variance (ANOVA) with a Dunnett or Scheffe post hoc test. Data with heterogeneous variance were analyzed by the Kruskal–Wallis rank test with a Dunnett or Scheffe
post hoc test. Statistical significance was designated at p < 0.05 or 0.01. - Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Transient differences in body weight were observed during the recovery period in rats originally receiving 5.0% L-ornithine monohydrochloride compared to controls; however, these differences were not observed during the treatment period and only occurred in one sex, and were thus deemed to be incidental.
- Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Transient differences in body weight and food consumption were observed during the recovery period in rats originally receiving 5.0% L-ornithine monohydrochloride compared to controls; however, these differences were not observed during the treatment period and only occurred in one sex, and were thus deemed to be incidental.
- Food efficiency:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Males receiving 5.0% L-ornithine monohydrochloride exhibited a transient decrease in food efficiency in week 1 of the treatment period compared to controls; however, this was not sustained and was not observed in females or in other dose groups. Therefore, this decrease was determined to be of no toxicological significance. Males receiving 5.0% L-ornithine monohydrochloride also exhibited a transient, statistically significant increase in food efficiency in week 2 of the recovery period. However, this was not observed in the treatment period or in females receiving the same dose, and therefore was deemed to be incidental.
- Water consumption and compound intake (if drinking water study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Not a drinking water study but non-treatment related effects examined and recorded.
A significant increase in water intake was observed in males receiving 5.0% L-ornithine monohydrochloride in week 1 of the treatment period compared to controls. A tendency toward high values of water intake also was noted in these males; however, no statistically significant increase in water intake was observed in females receiving 5.0% L-ornithine monohydrochloride. No clear differences in water intake were observed during the treatment period. - Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- A significant increase in the percentage of reticulocytes were observed in males receiving 5.0% L-ornithine monohydrochloride at the end of the treatment
period compared to controls; however, values remained within historical control ranges, it was not observed following the recovery period, and was not observed in females. Therefore, this observation was deemed to be incidental. At the end of the recovery period, a significant increase in the percentage of lymphocytes and a decrease in segmented neutrophils were observed in males receiving 5.0% L-ornithine monohydrochloride, and a significant decrease in the percentage of lymphocytes and a significant increase in segmented neutrophils were observed in females in the same dose group. As these changes were in opposite directions for the genders, they were deemed to be incidental in nature. - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- A significant decrease in serum chloride was observed in males receiving 2.5% and 5.0% L-ornithine monohydrochloride at the end of the treatment period compared to controls. Additionally, a significant increase in alkaline phosphatase activity was observed in females receiving 2.5% L-ornithine monohydrochloride compared to controls; however, this was not observed in females receiving 5.0% L-ornithine monohydrochloride and was thus deemed to be incidental. At the end of the recovery period, a significant decrease in the percentage of a2-globulin was observed in males in the 5.0% L-ornithine monohydrochloride group; however, this was not observed during the treatment period and was not observed in females. Therefore, this observation was deemed to be incidental.
- Urinalysis findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- In weeks 5 and 13 of the treatment period, a significant increase in urinary chloride was observed in males and females receiving 2.5% and 5.0% L-ornithine monohydrochloride compared to controls. At week 5 of the recovery period, a significant decrease in potassium and chloride excretion was observed in females receiving 5.0% L-ornithine monohydrochloride compared to controls. As the change in potassium excretion was not observed during the treatment period, this was deemed to be an incidental finding. The decrease in chloride excretion observed in females was in the opposite direction of that observed during the treatment period; therefore, the change was deemed to be of no toxicological significance. No other changes in urinalysis parameters were observed during the treatment or recovery periods.
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- At necropsy in week 13, a significant increase in the relative (to body) kidney weight was observed in males receiving 5.0% L-ornithine monohydrochloride compared to controls; however, this was unilateral, was not observed in females, and no significant differences were observed in absolute kidney weight. Therefore, this was deemed to be an incidental observation. At necropsy conducted following the 5-week recovery period, a significant increase in the absolute and relative kidney weight was observed in males receiving 5.0% L-ornithine monohydrochloride. Again, this was only observed unilaterally and was not observed in females. As such, this was concluded also to be an incidental observation.
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Incidental findings, only.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Histopathological changes observed at the end of the treatment period were noted in the stomach, liver, pancreas, pituitary, thyroid gland, spleen, cervical lymph node, kidney, eyeball, and thoracic wall; however, these were considered to be incidental based on the incidence of their occurrences and their pathological nature
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 3 445 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: All results
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 3 986 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: all results
- Key result
- Critical effects observed:
- no
- Conclusions:
- Based on the results of the study, a no-observed-adverse effect level (NOAEL) of 3445 and 3986 mg/kg body weight/day was established for male and female rats.
- Executive summary:
L-Ornithine monohydrochloride was evaluated in a rat 90-day oral toxicity study.
Rats were administered L-ornithine monohydrochloride at dietary concentrations of 0 (basal diet), 1.25%, 2.5%, or 5.0% for 90 days. No changes in body weight, food consumption, ophthalmoscopy, or hematology were observed. Transient increases in water intake and urinary volume, and a decrease in specific gravity were observed in males receiving 5.0% L-ornithine monohydrochloride; however, these were likely attributable to the central role of ornithine in the urea cycle and the consequent increase in urea production. A decrease in serum chloride concentration and an increase in urinary chloride excretion were observed; however, these were likely attributable to administration of the hydrochloride salt of ornithine and were not considered to be of any toxicological significance. No remarkable findings were noted at necropsy.
Based on the results of the study, a no-observed-adverse effect level (NOAEL) of 3445 and 3986 mg/kg body weight/day was established for male and female rats.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 3 445 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- Klimisch 1
- System:
- other: Entire organism
- Organ:
- other: Entire organism
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
- Justification for type of information:
- JUSTIFICATION FOR DATA WAIVING
Regarding inhalation, the combination of low volatility, a negative Log Kow and high water solubility suggests that absorption directly across the respiratory tract epithelium is unlikely.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
- Justification for type of information:
- JUSTIFICATION FOR DATA WAIVING
Regarding inhalation, the combination of low volatility, a negative Log Kow and high water solubility suggests that absorption directly across the respiratory tract epithelium is unlikely.
Reference
Repeated dose toxicity: dermal - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: dermal
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
- Justification for type of information:
- JUSTIFICATION FOR DATA WAIVING
[Specific explanation in addition to field 'Justification for data waiving']
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: dermal
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
- Justification for type of information:
- JUSTIFICATION FOR DATA WAIVING
[Specific explanation in addition to field 'Justification for data waiving']
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
Based on the results of the study, a no-observed-adverse effect level (NOAEL) of 3445 and 3986 mg/kg body weight/day was established for male and female rats.
The substance is practically non-toxic and does not meet the criteria for classification as to CLP.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.